PathAI

PathAI is a biotechnology company focused on AI-powered pathology diagnostics. Through its AISight® digital pathology image management system, it delivers intelligent pathology analysis solutions for pharmaceutical companies, pathology labs, and clinical diagnostics organizations. The platform uses deep learning algorithms to analyze pathology slides automatically, detecting tumors, quantifying biomarkers, and helping pathologists reach more precise diagnoses.

Key Features

• AISight®, a cloud-native digital pathology workflow platform with case management, image management, and AI analysis tools
• AI-driven tumor detection and biomarker quantification, supporting assessment of key markers such as PD-L1 expression
• Automated slide quality analysis, with the ArtifactDetect model identifying low-quality samples
• A collaborative network of more than 450 certified pathologists and AI models trained on more than 15 million labeled data points
• Drug and diagnostic development support services for biopharma

Use Cases In clinical diagnostics, pathologists using the PathAI platform can cut analysis time on complex cases by 35% while improving diagnostic consistency and accuracy. In drug development, pharmaceutical companies use the platform for biomarker discovery and efficacy evaluation, and 90% of top pharmaceutical companies have adopted its technology. In lab operations, digitized workflows markedly improve sample processing efficiency and quality control.

Unique Advantages PathAI holds FDA 510(k) clearance and CE marking, making it one of the few AI pathology platforms recognized by regulators for clinical diagnostics. The company has strategic partnerships with renowned institutions such as Quest Diagnostics, Northwestern Medicine, and the Cleveland Clinic, and has launched the Precision Pathology Network (PPN), which gives labs unified digital pathology infrastructure and early access to its AI algorithms.